The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of multiple ascending oral doses of AZD1236 given to healthy young subjects for 13 days and to evaluate the single-dose relative bioavailability of the oral suspension and oral tablet formulations.

Inclusion Criteria:

• Provision of signed informed consent prior to any study specific procedures
• Body Mass Index (BMI) between 19-27 kg/m2

Exclusion Criteria:

• Receipt of another investigational drug in the 4 months before dosing in this study
• Acute illness which requires medical intervention within 2 weeks of Visit 2.
• Abnormal resting BP and pulse rate (after resting for 10 minutes). Supine blood pressure > 140 mmHg systolic or >90 mmHg diastolic, pulse<= 50 or => 90 beats per minute